Browse News
Filter News
Found 123 articles
-
Aligos Therapeutics to Present Data on its Liver Disease Programs at the European Association for the Study of the Liver (EASL) Congress 2023
6/7/2023
Aligos Therapeutics, Inc. today announced that the company will present seven posters collectively highlighting data on its liver disease programs at the European Association for the Study of the Liver (EASL) Congress 2023, taking place in Vienna, Austria, June 21 – 24, 2023.
-
Follow along as BioSpace keeps you up-to-date on the latest pharma and biotech layoffs.
-
Aligos Therapeutics to Present at the Jefferies 2023 Healthcare Conference
5/24/2023
Aligos Therapeutics, Inc. announced that Lawrence M. Blatt, Ph.D., MBA, Chairman and CEO of Aligos, will present at the Jefferies Healthcare Conference on Thursday, June 8, 2023 at 8:00 a.m. ET.
-
Aligos Therapeutics Announces Research Collaboration and Development Agreement with Xiamen Amoytop Biotech Co. Ltd. for Use of Aligos’ Oligonucleotide Platform for the Treatment of Liver Diseases
5/12/2023
Aligos Therapeutics, Inc. announced that it has entered into a research collaboration and development agreement with Xiamen Amoytop Biotech Co. Ltd. for the use of Aligos’ oligonucleotide platform to discover, research and develop oligonucleotides for the treatment of liver diseases in the Greater China territory.
-
Aligos Therapeutics Reports Recent Business Progress and First Quarter 2023 Financial Results
5/4/2023
Aligos Therapeutics, Inc. reported recent business progress and financial results for the first quarter 2023.
-
Aligos Therapeutics to Announce First Quarter Results on May 4, 2023
4/27/2023
Aligos Therapeutics, Inc. (Nasdaq: ALGS, “Aligos”, the “Company”) today announced that it will report the Company’s first quarter 2023 financial results on Thursday, May 4, 2023, after the close of the U.S. financial markets.
-
Aligos Therapeutics to Present Data from Chronic Hepatitis B and Hepatocellular Carcinoma Programs at the European Association for the Study of the Liver (EASL) Congress 2023
4/11/2023
Aligos Therapeutics, Inc. announced that the company will present seven posters collectively highlighting data out of five of its liver disease programs at the European Association for the Study of the Liver Congress 2023, taking place in Vienna, Austria, June 21 – 24, 2023.
-
Aligos Therapeutics Presents Clinical Data from NASH Program at the 2023 Paris Hepatology Conference
3/29/2023
Aligos Therapeutics, Inc. (Nasdaq: ALGS) today announced that the company presented Phase 1 data for its thyroid receptor-beta (THR-ß) agonist candidate, ALG-055009, at the 15th Paris Hepatology Conference, taking place virtually March 27 – 29, 2023.
-
Aligos Therapeutics Reports Recent Business Progress and Fourth Quarter and Full Year 2022 Financial Results
3/9/2023
Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company focused on developing novel therapeutics to address unmet medical needs in liver and viral diseases, today reported recent business progress and financial results for the fourth quarter and full year 2022.
-
Aligos Therapeutics to Announce Fourth Quarter Results March 9, 2023
2/28/2023
Aligos Therapeutics, Inc. (Nasdaq: ALGS, “Aligos”, the “Company”) today announced that it will report the Company’s fourth quarter 2022 financial results on Thursday, March 9, 2023 after the close of the U.S. financial markets.
-
Aligos Therapeutics Presents Program Updates at the 32nd Conference of the Asian Pacific Association for the Study of the Liver
2/16/2023
Aligos Therapeutics, Inc. (Nasdaq: ALGS) today announced that the company is delivering several oral and poster presentations at the 32nd Conference of the Asian Pacific Association for the Study of the Liver (APASL), being held Feb 15 – 19 in Taipei, Taiwan at the Taipei International Convention Center.
-
Aligos Therapeutics to Present Program Updates at the 32nd Conference of the Asian Pacific Association for the Study of the Liver
2/14/2023
Aligos Therapeutics, Inc. (Nasdaq: ALGS) today announced that the company will deliver several oral and poster presentations at the 32nd Conference of the Asian Pacific Association for the Study of the Liver (APASL), being held Feb 15 – 19 in Taipei, Taiwan at the Taipei International Convention Center.
-
Aligos Therapeutics to Present at the SVB Securities Global Biopharma Conference
2/10/2023
Aligos Therapeutics, Inc. (Nasdaq: ALGS) today announced that Lawrence M. Blatt, Ph.D., MBA, Chairman and CEO of Aligos, will present at the virtual SVB Securities Global Biopharma Conference on Wednesday, February 15, 2023 at 5:00 p.m. ET.
-
Aligos Therapeutics Announces Strategic Reprioritization of NASH and COVID-19 Programs and Confirms Key Timelines and Extension of Cash Runway to Year-End 2024
2/8/2023
Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company focused on developing novel therapeutics to address unmet medical needs in NASH and viral diseases, today announced a portfolio reprioritization.
-
Aligos Therapeutics on Track to Complete Phase 2-Enabling Activities in 2023 for its Clinically Validated THR-ß Drug Candidate for NASH, ALG-055009
1/5/2023
Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company focused on developing novel therapeutics to address unmet medical needs in viral and liver diseases, today announced that the company remains on track to complete all Phase 2-enabling activities in 2023 for ALG-055009, its thyroid hormone receptor beta (THR-ß) drug candidate for nonalcoholic steatohepatitis (NASH).
-
Aligos Therapeutics Initiates Dosing with its Small Interfering RNA (siRNA) Drug Candidate, ALG-125755, in Subjects with Chronic Hepatitis B (CHB)Single and multiple ascending doses to be evaluated in CHB subjects throughout 2023
12/14/2022
Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company focused on developing novel therapeutics to address unmet medical needs in viral and liver diseases, reported today that dosing with ALG-125755, a small interfering RNA (siRNA) targeting the production of hepatitis B surface antigen (HBsAg), was initiated in subjects with chronic hepatitis B (CHB) in Study ALG-125755-501 (NCT05561530).
-
Aligos Therapeutics Presents Nonclinical Data for its Coronavirus Therapeutic Program at the 2022 Respi DART Meeting
12/8/2022
Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company focused on developing novel therapeutics to address unmet medical needs in viral and liver diseases, today announced that the company presented the progress to date on the development of an oral pan-coronavirus therapeutic at the 2022 Respi DART meeting that was held December 6 – 8, 2022, in Los Cabos, Mexico.
-
Aligos Therapeutics Reports Recent Business Progress and Third Quarter 2022 Financial Results
11/2/2022
Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company focused on developing novel therapeutics to address unmet medical needs in viral and liver diseases, today reported recent business progress and financial results for the third quarter, September 30, 2022.
-
Aligos Therapeutics to Present Nonclinical and Clinical Data for its Chronic Hepatitis B and NASH Portfolio at AASLD’s The Liver Meeting® 2022
10/21/2022
Aligos Therapeutics, Inc. today announced seven upcoming poster presentations at The Liver Meeting® (November 4-8, 2022), hosted by the American Association for the Study of Liver Diseases (AASLD).
-
Aligos Therapeutics to Announce Third Quarter Results November 2, 2022
10/19/2022
Aligos Therapeutics, Inc. (Nasdaq: ALGS, the “Company”) today announced that it will report the company’s third quarter 2022 financial results on Wednesday, November 2, 2022 after the close of the U.S. financial markets.